H.C. Wainwright analyst Sara Nik downgraded Cidara Therapeutics (CDTX) to Neutral from Buy without a price target after the company agreed to be acquired by Merck (MRK) in an all-cash transaction for $221.50 per share.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX: